SAM-e (S-Adenosyl methionine)

Share on facebook
Share on google
Share on twitter
Share on linkedin


  • In 2004 the Journal of Clinical Psychopharmacology published a 6-week trial in which 30 subjects with major depressive disorder who were already taking either an SSRI or venlafaxine received 800 to 1600 mg of SAM-e per day. The result was a 50 percent response rate and a 43 percent remission rate. [Source]
  • In 2015 Pharmacopsychiatry published a double-blind, placebo-controlled trial involving 51 males and 62 females which found that SAM-e was superior to a placebo in treating depression in men but not in women. [Source]
  • In 2010 The American Journal of Psychiatry published a 6-week, double-blind, placebo-controlled study in which 73 patients who did not respond to SSRI treatment were given 2 doses of 800 mg of SAM-e per day while they continued SSRI treatment. SAM-e performed better than a placebo in improving depression. [Source]
  • In 2002 The American Journal of Clinical Nutrition published a 2-part study involving 281 and 295 subjects (lasting 6 and 4 weeks, respectively) which found that both 1600 mg oral SAM-e and 400 mg intramuscular SAM-e performed as well as 150 mg/day of the tricyclic antidepressant, imipramine. SAM-e was also significantly better tolerated than imipramine. [Source]


  • In 2004 BMC Musculoskeletal Disorders published a double-blind study comparing 1200 of SAM-e to 200 mg of celecoxib (brand name, Celebrex) for 16 weeks in 56 patients with osteoarthritis of the knee. The results showed that SAM-e is as effective as celecoxib, though it has a slower onset. [Source]
  • In 2002 The Journal of Family Practice published a meta-analysis of 2 studies comparing SAM-e to NSAIDS and a placebo for the treatment of osteoarthritis. The data showed that SAM-e is comparable with NSAIDS for reducing pain and functional limitations associated with osteoarthritis and has the advantage of being much better tolerated. [Source]
  • In 2009 Clinical Therapeutics published an 8-week, double-blind study involving 134 patients which found that 1200 mg/day of SAM-e was as effective as 1000 mg/day of the NSAID (non-steroidal anti-inflammatory drug), nabumetone in treating osteoarthritis of the knee. [Source]

Erectile Dysfunction

  • In 2012 European Psychiatry published a double-blind, placebo-controlled trial in which patients not responding to SSRI treatment were given additional treatment of SAM-e or a placebo. The authors note that 58-73 percent of those receiving antidepressants experience sexual dysfunction. In this study SAM-e significantly lowered erectile dysfunction compared to a placebo. The researchers also note that SAM-e can also have a positive benefit on male arousal independent of depressive symptoms. [Source]

Protection against alcohol-related liver disease

  • In 2003 The Journal of Nutritional Biochemistry published an animal study which investigated the effect of SAM-e on mice with liver injury due to acute alcohol administration. SAM-e was able to significantly reduce liver injury by raising antioxidant levels. [Source]

Depression – HIV patients

  • In 2004 BMC Psychiatry published an 8-week, open trial in which 20 HIV-positive patients saw an acute reduction in depressive symptoms after taking SAM-e. [Source]

Hepatitis C

  • In 2010 the Public Library of Science published a pilot study in which 29 CHC (chronic hepatitis C) patients who failed previous therapy with an antiviral drug were treated SAM-e along with other treatments. The researchers concluded that the addition of SAM-e improved the body’s response to CHC. [Source]



Become a Health Buff!

Get email updates when we publish new content

We will never give away, trade or sell your email address. You can unsubscribe at any time.

Share on facebook
Share on twitter
Share on linkedin
Share on email